Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer

Jan Kroon, Jan Kroon, Sander Kooijman, Nam-Joon Cho, Gerrit Storm, Gabri van der Pluijm

Research output: Contribution to journalArticleAcademicpeer-review

18 Citations (Scopus)

Abstract

Currently, the clinical utility of taxane-based drug formulations in castration-resistant prostate cancer (CRPC) is severely limited by acquired chemotherapy resistance, dose-limiting toxicities, and nonresponders. Therefore, approaches to improve taxane-based chemotherapy are desperately required. In this review, we highlight the strategies that aim to overcome these limitations, such as bypassing therapy resistance, targeted drug delivery, and adequate prediction of therapy response. The involvement of the apoptotic pathway, ABC transporters, the glucocorticoid receptor (GR) axis, androgen receptor (AR) splicing, epithelial plasticity, and cancer stem cells in mediating taxane-resistance are outlined. Furthermore, passive and active targeted nanomedicinal drug delivery strategies and the use of circulating tumor cells in predicting docetaxel responses are discussed. Finally, recent advances towards clinical translation of these approaches in CRPC are reviewed.
Original languageEnglish
Pages (from-to)451-462
JournalTrends in pharmacological sciences
Volume37
Issue number6
DOIs
Publication statusPublished - 2016

Fingerprint

Chemotherapy
Castration
Prostatic Neoplasms
docetaxel
Drug Therapy
Circulating Neoplastic Cells
Drug Compounding
ATP-Binding Cassette Transporters
Neoplastic Stem Cells
Glucocorticoid Receptors
Androgen Receptors
Stem cells
Drug Resistance
Plasticity
Toxicity
Tumors
Cells
Therapeutics
Pharmaceutical Preparations
taxane

Keywords

  • IR-103722
  • METIS-320768

Cite this

Kroon, Jan ; Kroon, Jan ; Kooijman, Sander ; Cho, Nam-Joon ; Storm, Gerrit ; van der Pluijm, Gabri. / Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer. In: Trends in pharmacological sciences. 2016 ; Vol. 37, No. 6. pp. 451-462.
@article{d6fa7c9b2ae142b8b637e035f81b147d,
title = "Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer",
abstract = "Currently, the clinical utility of taxane-based drug formulations in castration-resistant prostate cancer (CRPC) is severely limited by acquired chemotherapy resistance, dose-limiting toxicities, and nonresponders. Therefore, approaches to improve taxane-based chemotherapy are desperately required. In this review, we highlight the strategies that aim to overcome these limitations, such as bypassing therapy resistance, targeted drug delivery, and adequate prediction of therapy response. The involvement of the apoptotic pathway, ABC transporters, the glucocorticoid receptor (GR) axis, androgen receptor (AR) splicing, epithelial plasticity, and cancer stem cells in mediating taxane-resistance are outlined. Furthermore, passive and active targeted nanomedicinal drug delivery strategies and the use of circulating tumor cells in predicting docetaxel responses are discussed. Finally, recent advances towards clinical translation of these approaches in CRPC are reviewed.",
keywords = "IR-103722, METIS-320768",
author = "Jan Kroon and Jan Kroon and Sander Kooijman and Nam-Joon Cho and Gerrit Storm and {van der Pluijm}, Gabri",
note = "review article",
year = "2016",
doi = "10.1016/j.tips.2016.03.003",
language = "English",
volume = "37",
pages = "451--462",
journal = "Trends in pharmacological sciences",
issn = "0165-6147",
publisher = "Elsevier",
number = "6",

}

Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer. / Kroon, Jan; Kroon, Jan; Kooijman, Sander; Cho, Nam-Joon; Storm, Gerrit; van der Pluijm, Gabri.

In: Trends in pharmacological sciences, Vol. 37, No. 6, 2016, p. 451-462.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Improving Taxane-Based Chemotherapy in Castration-Resistant Prostate Cancer

AU - Kroon, Jan

AU - Kroon, Jan

AU - Kooijman, Sander

AU - Cho, Nam-Joon

AU - Storm, Gerrit

AU - van der Pluijm, Gabri

N1 - review article

PY - 2016

Y1 - 2016

N2 - Currently, the clinical utility of taxane-based drug formulations in castration-resistant prostate cancer (CRPC) is severely limited by acquired chemotherapy resistance, dose-limiting toxicities, and nonresponders. Therefore, approaches to improve taxane-based chemotherapy are desperately required. In this review, we highlight the strategies that aim to overcome these limitations, such as bypassing therapy resistance, targeted drug delivery, and adequate prediction of therapy response. The involvement of the apoptotic pathway, ABC transporters, the glucocorticoid receptor (GR) axis, androgen receptor (AR) splicing, epithelial plasticity, and cancer stem cells in mediating taxane-resistance are outlined. Furthermore, passive and active targeted nanomedicinal drug delivery strategies and the use of circulating tumor cells in predicting docetaxel responses are discussed. Finally, recent advances towards clinical translation of these approaches in CRPC are reviewed.

AB - Currently, the clinical utility of taxane-based drug formulations in castration-resistant prostate cancer (CRPC) is severely limited by acquired chemotherapy resistance, dose-limiting toxicities, and nonresponders. Therefore, approaches to improve taxane-based chemotherapy are desperately required. In this review, we highlight the strategies that aim to overcome these limitations, such as bypassing therapy resistance, targeted drug delivery, and adequate prediction of therapy response. The involvement of the apoptotic pathway, ABC transporters, the glucocorticoid receptor (GR) axis, androgen receptor (AR) splicing, epithelial plasticity, and cancer stem cells in mediating taxane-resistance are outlined. Furthermore, passive and active targeted nanomedicinal drug delivery strategies and the use of circulating tumor cells in predicting docetaxel responses are discussed. Finally, recent advances towards clinical translation of these approaches in CRPC are reviewed.

KW - IR-103722

KW - METIS-320768

U2 - 10.1016/j.tips.2016.03.003

DO - 10.1016/j.tips.2016.03.003

M3 - Article

VL - 37

SP - 451

EP - 462

JO - Trends in pharmacological sciences

JF - Trends in pharmacological sciences

SN - 0165-6147

IS - 6

ER -